Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-na�ve Subjects With Type 2 Diabetes (SUSTAIN�1)

This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes. (SUSTAIN™ 1-Monotherapy).


Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
Enrollment: 388
Study Start Date: February 2014
Study Completion Date: May 2015
Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)

Arms:
- Experimental: Semaglutide 1.0 mg
- Experimental: Semaglutide 0.5 mg
- Placebo Comparator: Semaglutide placebo 1.0 mg
- Placebo Comparator: Semaglutide placebo 0.5 mg